Sigyn Therapeutics CardioDialysis™ FAQ: New Cardiovascular Treatment Approach
TL;DR
Sigyn Therapeutics' CardioDialysis offers dialysis clinics a new $2.8 billion revenue stream by extending ESRD patient lives while reducing cardiovascular mortality.
CardioDialysis uses existing dialysis machines to remove inflammatory molecules and cholesterol-transporting lipoproteins through broad-spectrum blood purification during regular treatments.
CardioDialysis could transform dialysis clinics into treatment centers that extend patient lives and reduce cardiovascular deaths among vulnerable ESRD populations.
CardioDialysis leverages 7,500 existing dialysis clinics to treat cardiovascular disease with a device approach proven to reduce major cardiac events by 59-95%.
Found this article helpful?
Share it with your network and spread the knowledge!
CardioDialysis™ is a precedent-based medical device developed by Sigyn Therapeutics to treat cardiovascular disease by reducing inflammatory molecules and cholesterol-transporting lipoproteins that contribute to heart attacks, strokes, and other Major Adverse Cardiovascular Events.
CardioDialysis™ addresses cardiovascular disease, the leading cause of death globally, and offers a broad-spectrum mechanism that overcomes limitations of single-target pharmaceutical drugs in a market exceeding $100 billion annually.
The device uses blood purification to reduce circulating inflammatory molecules that fuel cardiovascular disease progression while simultaneously lowering levels of cholesterol-transporting lipoproteins that contribute to heart attacks and strokes.
Initial FDA human studies will enroll kidney dialysis patients, specifically end-stage renal disease (ESRD) patients who face a 67% cardiovascular disease mortality rate according to the U.S. Renal Data System.
CardioDialysis™ is designed for deployment on dialysis machines located within more than 7,500 dialysis clinics in the United States, potentially transforming them into Renal and CardioDialysis™ treatment centers.
CardioDialysis™ offers a broad-spectrum mechanism that overcomes inherent limitations of single-target pharmaceutical drugs and leverages blood purification technology with proven ability to reduce Major Adverse Cardiovascular Disease Events.
The annual market for MACE-reducing therapies exceeds $100 billion, with an estimated 550,000 ESRD patients receiving approximately 85 million dialysis treatments annually in the U.S. alone.
This represents a shift in therapeutic focus toward cardiovascular disease, leveraging FDA-approved precedent and providing a pathway into a larger market opportunity while being less burdensome to enroll subjects for FDA approval studies.
Previous treatment indications included sepsis, drug-resistant bacterial infections, and life-threatening viral infections, which collectively account for 10.1% of ESRD patient deaths according to U.S. Renal Data System data.
Curated from NewMediaWire
